Kim Ji Won, Han Sun Hyup, Son Byeong Jae, Rim Tyler Hyungtaek, Keum Ki Chang, Yoon Jin Sook
Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea.
Yonsei University College of Medicine, Seoul, Korea.
Graefes Arch Clin Exp Ophthalmol. 2016 May;254(5):991-8. doi: 10.1007/s00417-016-3280-7. Epub 2016 Feb 15.
To compare the efficacy and safety of combination therapy with orbital irradiation and systemic steroids versus steroid monotherapy in the management of active Graves' orbitopathy (GO).
The clinical charts of 127 patients with active inflammation due to GO who received intravenous steroid pulse therapy as a first-line treatment with or without orbital radiotherapy between 2010 and 2014 were reviewed. Patients were divided into two treatment groups: 1) combined orbital radiotherapy and steroid pulse therapy (SRT group) and 2) steroid pulse therapy only (ST group). Primary outcome measures included clinical activity score (CAS); NOSPECS classification; ocular motility impairment; and exophthalmos at 1, 3, 6, and 12 months after treatment. The secondary outcome measure was the change in orbital, extraocular muscle (EOM), and fat volume after treatment measured by orbit computed tomography.
Sixty-eight patients were included in the SRT group, and 59 patients were in the ST group. In both treatments, CAS and NOSPECS were significantly reduced. In the comparison of the degree of change from baseline between the groups, the SRT group demonstrated more improvement in NOSPECS and scores of ocular motility. Orbital, EOM, and fat volume significantly decreased in the SRT group; however, only fat volume was reduced in the ST group. Compressive optic neuropathy after treatment developed in 0 % of the SRT group and 3.4 % (2/59) of the ST group. Reactivation of inflammation occurred in 11.8 % (8/68) of the SRT group and 28.8 % (17/59) of the ST group.
Orbital radiotherapy in combination with steroid treatment significantly improved ocular motility by reducing EOM volume in patients with active GO.
比较眼眶照射联合全身用类固醇与单纯类固醇治疗在活动期格雷夫斯眼病(GO)管理中的疗效和安全性。
回顾了2010年至2014年间127例因GO导致活动性炎症且接受静脉类固醇脉冲治疗作为一线治疗(有或无眼眶放疗)的患者的临床病历。患者分为两个治疗组:1)眼眶放疗联合类固醇脉冲治疗组(SRT组)和2)仅类固醇脉冲治疗组(ST组)。主要结局指标包括临床活动评分(CAS);NOSPECS分级;眼球运动障碍;以及治疗后1、3、6和12个月时的眼球突出度。次要结局指标是治疗后通过眼眶计算机断层扫描测量的眼眶、眼外肌(EOM)和脂肪体积的变化。
SRT组纳入68例患者,ST组纳入59例患者。两种治疗中,CAS和NOSPECS均显著降低。在比较两组相对于基线的变化程度时,SRT组在NOSPECS和眼球运动评分方面改善更明显。SRT组的眼眶、EOM和脂肪体积显著减小;然而,ST组仅脂肪体积减小。治疗后SRT组未发生压迫性视神经病变,ST组为3.4%(2/59)。SRT组炎症复发率为11.8%(8/68),ST组为28.8%(17/59)。
眼眶放疗联合类固醇治疗通过减少活动期GO患者的EOM体积显著改善了眼球运动。